Skip to main content
Clinical Trials/NCT00351052
NCT00351052
Completed
Phase 3

A 24-Week, Randomized, Multicenter, Parallel-Group, Double-Blind, Vehicle-Controlled Study on Pimecrolimus Cream 1% Assessing the Steroid-Sparing Effect in the Long Term Management of Pediatric Patients With Severe Atopic Dermatitis

Novartis0 sites184 target enrollmentDecember 2001

Overview

Phase
Phase 3
Intervention
Pimecrolimus
Conditions
Atopic Dermatitis
Sponsor
Novartis
Enrollment
184
Primary Endpoint
Corticoid-sparing effect of pimecrolimus cream 1%
Status
Completed
Last Updated
18 years ago

Overview

Brief Summary

This study will investigate the steroid sparing effect of pimecrolimus cream 1% in pediatric atopic dermatitis

Registry
clinicaltrials.gov
Start Date
December 2001
End Date
September 2004
Last Updated
18 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Novartis

Eligibility Criteria

Inclusion Criteria

  • Outpatients aged 2 to \< 18 years with severe AD (score 8 or 9 according to Rajka and Langeland)
  • responded to 21 days of treatment with prednicarbate cream 0.25% during screening phase

Exclusion Criteria

  • Patients who had received phototherapy, systemic or topical therapy or systemic corticosteroids shortly prior to study

Arms & Interventions

1

Pimecrolimus

Intervention: Pimecrolimus

2

Vehicle

Intervention: Placebo

Outcomes

Primary Outcomes

Corticoid-sparing effect of pimecrolimus cream 1%

Secondary Outcomes

  • safety of pimecrolimus cream 1%
  • atopic dermatitis control
  • quality of life

Similar Trials